HIV-1-INFECTION

This study is testing a multi-part strategy to help the immune system control HIV without daily antiviral pills. It combines a vaccine, an immune-stimulating drug, and two lab-made antibodies. The goal is to see if this approach can keep HIV levels low when participants temporari…

This study is testing whether two antibody medications given by IV every 8 weeks can maintain HIV suppression as effectively as daily oral pills. The trial involves 75 adults whose HIV is already well-controlled with standard medication. Researchers want to see if this new approa…

This study aims to find the best treatment strategy for people with HIV whose current dolutegravir (DTG) medication is no longer fully effective due to drug resistance. Researchers will randomly assign 392 participants, including some children, to either continue their DTG-based …

This study is testing if a medication already used for diabetes and kidney disease can improve blood flow in the heart for women with HIV. Researchers want to see if better blood flow can lower their higher risk of heart attacks. The study will compare two groups: one receiving h…

This is an early-stage study to check the safety and initial antiviral effect of a new HIV medication called GS-3242. It will involve about 30 adults living with HIV who are not currently on treatment. Researchers will measure how the drug affects the amount of virus in the blood…

This study is testing a long-acting HIV medicine called lenacapavir in children and teenagers who have been treated before and whose current medicines are not fully working. Researchers want to see if the drug is safe, how it behaves in the body, and if it helps control the virus…

This study aims to find the best way to manage HIV when the preferred first-line drug, dolutegravir, isn't fully suppressing the virus. It will follow 6,600 people in four African countries who have high virus levels despite being on treatment. Researchers will see if intensive c…

This study is testing a new combination of two HIV drugs, bictegravir and lenacapavir, in children and teenagers whose HIV is already well-controlled. The main goals are to find the right dose for young people, see how the drugs move through their bodies, and check for side effec…

This study provides continued access to HIV medications for children and adolescents who have successfully completed an earlier Gilead HIV treatment trial. Its main purpose is to allow these young participants to keep receiving their effective treatment while researchers monitor …

This is a first-in-human study to test the safety and blood levels of a new antibody called BNT351. It will involve 61 adults, both with and without HIV, to see if the antibody is safe and if it can reduce the amount of HIV in the blood of those living with the virus. The study i…

This study is testing a new oral drug, STP0404, to see if it safely lowers the amount of HIV virus in people who are not currently on treatment. It will involve 36 adults with HIV-1 who have taken little or no HIV medication before. Researchers will measure the change in virus le…

This study is testing a new oral medication called CL-197 for people with HIV who have never taken any HIV drugs before. The main goal is to see how well a single dose lowers the amount of virus in the blood and to check if it is safe. Researchers will also measure how the drug m…

This large, late-stage trial is testing if a new HIV drug combination (doravirine) works as well as a widely used current treatment (dolutegravir) for people starting therapy for the first time. It will enroll 610 adults across six countries and follow them for nearly two years. …

This study aims to understand how well HIV prevention pills (PrEP) work in everyday life across Italy. It will follow 5,000 adults who are HIV-negative and using PrEP to see how many new HIV infections occur, monitor side effects, and identify what helps or hinders people from st…

This study aims to find a safe dose of a three-drug combination pill (B/F/TAF) to prevent HIV infection in newborns whose mothers have HIV. It will enroll 16 full-term, uninfected newborns to check for side effects and measure how the drug moves through their bodies. The goal is …

This early-stage study is testing the safety of a vaginal probiotic called MucoCept-CVN, which is designed to prevent HIV infection in women. The probiotic contains a modified bacteria that continuously produces an anti-HIV drug. Researchers will enroll 12 healthy women to test d…

This study is testing a phone-based therapy to help people living with HIV reduce unhealthy alcohol use and improve mental health. Researchers will compare a new therapy called Acceptance and Commitment Therapy (ACT) against a standard brief alcohol intervention. The goal is to s…

This study aims to understand how cognitive-behavioral therapy (a type of talk therapy) for depression affects the gut microbiome, immune system, and brain function in people living with HIV. Researchers will enroll 150 adults with HIV and depression to measure changes in their g…

This study aims to understand how mothers living with HIV in the U.S. make decisions about feeding their babies, including breastfeeding. Researchers will interview mothers, healthcare providers, and family members, and follow a large group of mothers and infants to learn about t…

This study aims to understand how two main cannabis compounds, THC and CBD, affect thinking skills like decision-making, attention, and motivation in people living with HIV. Researchers will compare 138 participants with and without HIV who don't use cannabis often, giving them a…